74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
C Champions Oncology Inc
C
Closed
Sector Healthcare
10.17 -3.05
Overview
Share price change
24h
Min
10.02
Max
10.25
Income | -585K 728K |
|---|---|
Sales | -572K 13M |
EPS | 0.05 |
Profit margin | 5.397 |
Employees | 210 |
EBITDA | -647K 1.1M |
Next Earnings | 11 Mar 2025 |
|---|
Market Cap | 148M |
|---|---|
Previous open | 13.22 |
Previous close | 10.17 |
News Sentiment
By Acuity
50%
50%
157 / 393 Healthcare
Technical Score
By Trading Central
Confidence
Very Strong Bearish Evidence
Champions Oncology Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Champions Oncology Inc Forecast
Sentiment
By Acuity
157 / 393 Healthcare
News Sentiment
Neutral
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Champions Oncology Inc
Champions Oncology, Inc., a technology-enabled research company, provides transformative technology solutions for drug discovery and development in the United States. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. In addition, it offers Lumin Bioinformatics, an oncology data-driven software program which contains comprehensive information derived from research services and clinical studies. The company markets its products through internet, word of mouth, and sales force to pharmaceutical and biotechnology companies. Champions Oncology, Inc. was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. The company was incorporated in 1985 and is headquartered in Hackensack, New Jersey.
